Patent ID: 8119651

Claim:
A method of ameliorating or alleviating metabolic syndrome in an individual in need thereof, said method comprising administering a therapeutically effective amount of a vascular adhesion protein 1 (VAP-1) semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor selected from the group consisting of vitamin B1, its derivative 3-(2-aminobenzyl)-5-(2-hydroxyethyl)-4-methyl-thiazolium chloride hydrochloride, and its precursor benfotiamine to said individual, wherein said metabolic syndrome is characterized by (a) central obesity as measured by waist circumference greater than 102 cm for males and greater than 88 cm for females and (b) two of the following: (i) fasting plasma glucose greater than 6.1 mmol/l, (ii) blood triglycerides greater than 1.7 mmol/l, (iii) blood HDL cholesterol less than 1.03 mmol/l for males and less than 1.29 mmol/l for females and (iv) blood pressure greater than 130/85 mm Hg.